1 de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S and Sartor O for the TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 376(9747): 1147-1154, 2010. PMID: 20888992. DOI: 10.1016/S0140-6736(10)61389-X
2 Altieri DC and Marchisio C: Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 79(11): 1327-1333, 1999. PMID: 10576203.
3 Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin expressed in cancer and lymphoma. Nat Med 3(8): 917-921, 1997. PMID: 9256286. DOI: 10.1038/nm0897-917
4 Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M and Sasamata M: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67(17): 8014-8021, 2007. PMID: 17804712. DOI: 10.1158/0008-5472.CAN-07-1343
5 Ryan BM, O’Donovan N and Duffy MJ: Survivin: A new target for anticancer therapy. Cancer Treat Rev 35(7): 553-562, 2009. PMID: 19559538. DOI: 10.1016/j.ctrv.2009.05.003
6 Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F: Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3(2): 179-197, 2012. PMID: 22773958.
7 Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M: Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 35(6): 787-792, 2011. PMID: 21237508. DOI: 10.1016/j.leukres.2010.11.016
8 Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102(3): 614-621, 2011. PMID: 21205082. DOI: 10.1111/j.1349-7006.2010.01834.x
9 Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N and Sasamata M: Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 17(16): 5423-5431, 2011. PMID: 21737502. DOI: 10.1158/1078-0432.CCR-10-3410
10 Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H and Sasamata M: YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22(5): 454-462,2011. PMID: 21389848. DOI: 10.1097/CAD.0b013e328344ac68
11 Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M and Nakagawa K: Marked anti-tumour activity of the combination of YM155, a novel surviving suppressant, and platinum-based drugs. Br J Cancer 103: 36-42, 2010. PMID: 20517311. DOI: 10.1038/sj.bjc.6605713
12 Na YS, Yang SJ, Kim SM, Jung KA, Moon JH, Shin JS, Yoon DH, Hong YS, Ryu MH, Lee JL, Lee JS and Kim TW: YM155 induces EGFR suppression in pancreatic cancer cells. PLoS One 7(6): e38625, 2012. PMID: 22723871. DOI: 10.1371/journal.pone.0038625
13 Kaneko R, Tsuji N, Asanuma K, Tanabe H, Kobayashi D and Watanabe N: Survivin down-regulation plays a crucial role in 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitor- induced apoptosis in cancer. J Biol Chem 282(27): 19273-19281, 2007. PMID: 17472962. DOI: 10.1074/jbc.M610350200
14 O’Connor DS, Wall NR, Porter AC and Altieri DC: A p34cdc2 survival checkpoint in cancer. Cancer Cell 2(1): 43-54, 2002. PMID: 12150824. DOI: 10.1016/s1535-6108(02)00084-3
15 Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM, Hong YS, Kim KP, Lee JL, Suh C, Lee JS and Kim TW: The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 32(5): 1681-1688, 2012. PMID: 22593446.
16 Koike H, Nitta T, Sekine Y, Arai S, Furuya Y, Nomura M, Matsui H, Shibata Y, Ito K, Oyama T and Suzuki K: YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol 140(10): 1705-1713, 2014. PMID: 24916171. DOI: 10.1007/s00432-014-1734-z
17 Nitta T, Koike H, Miyao T, Miyazawa Y, Kato H, Furuya Y, Sekine Y and Suzuki K: YM155 reverses statin resistance in renal cancer by reducing expression of survivin. Anticancer Res 37(1): 75-80, 2017. PMID: 28011476. DOI: 10.21873/anticanres.11291
18 Kita A, Nakahara T, Takeuchi M, Kinoyama I, Yamanaka K, Minematsu T, Mitsuoka K, Fushiki H, Miyoshi S, Sasamata M and Miyaka K: Survivin suppressant: A promising target for cancer therapy and pharmacological profiles of YM155. Folia Pharmacol Jpn 136(4): 198-203, 2010. PMID: 20948154. DOI: 10.1254/fpj.136.198